Skip to Content

Publications 2014


Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 2015 Jul 23;34(30):3968-76. doi: 10.1038/onc.2014.328. Epub 2014 Oct 6. PubMed PMID: 25284585; PubMed Central PMCID: PMC4387124.

Vassilopoulos A, Tominaga Y, Kim HS, Lahusen T, Li B, Yu H, Gius D, Deng CX.WEE1 murine deficiency induces hyper-activation of APC/C and results in genomic instability and carcinogenesis. Oncogene. 2015 Jun 4;34(23):3023-35. doi:10.1038/onc.2014.239. Epub 2014 Aug 4. PubMed PMID: 25088202.

Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015 May;28(5):662-9. doi: 10.1038/modpathol.2014.141. Epub 2014 Dec 12. PubMed PMID:  25502729; PubMed Central PMCID: PMC4416977.

Cheung YY, Nickels ML, McKinley ET, Buck JR, Manning HC. High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module. Appl Radiat Isot. 2015 Mar;97:47-51. doi: 10.1016/j.apradiso.2014.11.011. Epub 2014 Dec 15. PubMed PMID: 25531913.

Felix DD, Gore JC, Yankeelov TE, Peterson TE, Barnes S, Whisenant J, Weis J, Shoukouhi S, Virostko J, Nickels M, McIntyre JO, Sanders M, Abramson V, Tantawy MN. Detection of breast cancer microcalcification using (99m)Tc-MDP SPECT or Osteosense 750EX FMT imaging. Nucl Med Biol. 2015 Mar;42(3):269-73. doi: 10.1016/j.nucmedbio.2014.11.010. Epub 2014 Dec 6. PubMed PMID: 25533764.

Wang Q, Jia P, Cheng F, Zhao Z. Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer. Genes Chromosomes Cancer. 2015 Feb;54(2):110-21. doi: 10.1002/gcc.22224. Epub 2014 Nov 19. PubMed PMID: 25407423.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5. PubMed PMID: 25480943; PubMed Central PMCID: PMC4297507.

Rosenkrantz AB, Mendiratta-Lala M, Bartholmai BJ, Ganeshan D, Abramson RG, Burton KR, Yu JP, Scalzetti EM, Yankeelov TE, Subramaniam RM, Lenchik L. Clinical utility of quantitative imaging. Acad Radiol. 2015 Jan;22(1):33-49. doi: 10.1016/j.acra.2014.08.011. Epub 2014 Oct 22. Review. PubMed PMID: 25442800; PubMed Central PMCID: PMC4259826.

Xu Y, Guo X, Sun J, Zhao Z. Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. Bioinformatics. 2015 Jan 1;31(1):84-93. doi: 10.1093/bioinformatics/btu603. Epub  2014 Sep 5. PubMed PMID: 25192743; PubMed Central PMCID: PMC4271146.

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16. Review. PubMed PMID: 25043972; PubMed Central PMCID: PMC4270831.

Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015 Jan;145:76-84. doi: 10.1016/j.pharmthera.2014.08.003. Epub 2014 Aug 27. Review. PubMed PMID: 25172548; PubMed Central PMCID: PMC4340597.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17. PubMed PMID: 25401474; PubMed Central PMCID: PMC4348968.

Jiang J, Jia P, Zhao Z, Shen B. Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics. 2014 Nov 24;15:1015. doi: 10.1186/1471-2164-15-1015. PubMed PMID: 25418933; PubMed Central PMCID: PMC4258300.

Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, Bao PP, Cai H, Zhao Z, Balko J, Zheng W, Lu W, Shu XO. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast Cancer Res Treat. 2014 Nov;148(1):211-20. doi: 10.1007/s10549-014-3127-z. Epub 2014 Oct 4. PubMed PMID: 25281216; PubMed Central PMCID: PMC4200532.

Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest. 2014 Nov;124(11):4737-52. doi: 10.1172/JCI76375. Epub 2014 Sep 24. PubMed PMID: 25250573; PubMed Central PMCID: PMC4347249.

Yu H, Mitra R, Yang J, Li Y, Zhao Z. Algorithms for network-based identification of differential regulators from transcriptome data: a systematic evaluation. Sci China Life Sci. 2014 Nov;57(11):1090-102. doi: 10.1007/s11427-014-4762-7. Epub 2014 Oct 18. PubMed PMID: 25326829.

Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y. Detection of internal exon deletion with exon Del. BMC Bioinformatics.2014 Oct 16;15:332. doi: 10.1186/1471-2105-15-332. PubMed PMID: 25322818; PubMed Central PMCID: PMC4288651.

Mayer IA, Arteaga CL. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer? J Clin Oncol. 2014 Sep 20;32(27):2932-4. PubMed PMID: 25071103.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014 Sep 15;74(18):5184-94. doi: 10.1158/0008-5472.CAN-14-0663. Epub 2014 Aug 6. PubMed PMID: 25100563; PubMed Central PMCID: PMC4167558.

Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep. 2014 Sep 1;6(3):154-158. PubMed PMID: 25419441; PubMed Central PMCID: PMC4235783.

Grieb BC, Chen X, Eischen CM. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res. 2014 Sep;12(9):1216-24. doi: 10.1158/1541-7786.MCR-14-0069. Epub 2014 May 27. PubMed PMID: 24866769; PubMed Central PMCID: PMC4163510.

Jiang J, Jia P, Shen B, Zhao Z. Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget. 2014 Aug 15;5(15):6168-77. PubMed PMID: 25026280; PubMed Central PMCID: PMC4171620.

Cheng F, Jia P, Wang Q, Lin CC, Li WH, Zhao Z. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol. 2014 Aug;31(8):2156-69. doi: 10.1093/molbev/msu167. Epub 2014 May 31. PubMed PMID: 24881052; PubMed Central PMCID: PMC4104318.

Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, Xiao H, Eischen CM. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.Cancer Res. 2014 Jul 1;74(13):3591-602. doi: 10.1158/0008-5472.CAN-13-2149. Epub 2014 May 1. PubMed PMID: 24786788; PubMed Central PMCID: PMC4079748.

Wilson GH 3rd, Gore JC, Yankeelov TE, Barnes S, Peterson TE, True JM, Shokouhi S, McIntyre JO, Sanders M, Abramson V, Ngyuen TQ, Mahadevan-Jansen A, Tantawy MN. An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using (18)F-NaF. J Nucl Med. 2014 Jul;55(7):1138-43. doi: 10.2967/jnumed.114.139170. Epub 2014 May 15. PubMed PMID: 24833491; PubMed Central PMCID: PMC4320039.

Cheng F, Jia P, Wang Q, Zhao Z. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget. 2014 Jun 15;5(11):3697-710. PubMed PMID: 25003367; PubMed Central PMCID: PMC4116514.

Su PF, Li CI, Shyr Y. Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Comput Stat Data Anal. 2014 Jun 1;74:39-51. PubMed PMID: 24567661; PubMed Central PMCID: PMC3931470.

Atuegwu NC, Li X, Arlinghaus LR, Abramson RG, Williams JM, Chakravarthy AB, Abramson VG, Yankeelov TE. Longitudinal, intermodality registration of quantitative breast PET and MRI data acquired before and during neoadjuvant chemotherapy: preliminary results. Med Phys. 2014 May;41(5):052302. doi: 10.1118/1.4870966. PubMed PMID: 24784395; PubMed Central PMCID: PMC4000383.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24. PubMed PMID: 24663045; PubMed Central PMCID: PMC3986383.

Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res. 2014 Apr 15;20(8):2126-35. doi: 10.1158/1078-0432.CCR-13-2444. Epub 2014 Feb 26. PubMed PMID: 24573549; PubMed Central PMCID: PMC3989451.

Whisenant JG, Ayers GD, Loveless ME, Barnes SL, Colvin DC, Yankeelov TE. Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging. 2014 Apr;32(3):245-9. doi: 10.1016/j.mri.2013.10.013. Epub 2013 Dec 14. PubMed PMID: 24433723; PubMed Central PMCID: PMC3939718.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9. PubMed PMID: 23661583; PubMed Central PMCID: PMC3742614.

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025. Review. PubMed PMID: 24651011; PubMed Central PMCID: PMC4018830.

Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res. 2014 Mar 1;74(5):1404-15. doi: 10.1158/0008-5472.CAN-13-1296. Epub 2014 Jan 2. PubMed PMID: 24385212; PubMed Central PMCID: PMC4149913.

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014 Feb 15;20(4):782-90. doi: 10.1158/1078-0432.CCR-13-0583. Review. PubMed PMID: 24536073; PubMed Central PMCID: PMC3962777.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. PubMed PMID: 24356096; PubMed Central PMCID: PMC3946308.

Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. J Biomed Opt. 2014 Feb;19(2):025001. doi: 10.1117/1.JBO.19.2.025001. PubMed PMID: 24496495; PubMed Central PMCID: PMC3913568.

Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601. PubMed PMID: 24451154; PubMed Central PMCID: PMC3978602.

Su PF, Chi Y. Marginal regression approach for additive hazards models with clustered current status data. Stat Med. 2014 Jan 15;33(1):46-58. doi:10.1002/sim.5914. Epub 2013 Aug 2. PubMed PMID: 23913626; PubMed Central PMCID:PMC3918483.

Rexer BN, Arteaga CL. Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. Breast Cancer Res. 2014;16(2):303. PubMed PMID: 25032256; PubMed Central PMCID: PMC4053204.

Jia P, Wang Q, Chen Q, Hutchinson KE, Pao W, Zhao Z. MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biol. 2014;15(10):489. PubMed PMID: 25348067; PubMed Central PMCID: PMC4226881.

Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014 Jan;232(2):142-50. doi: 10.1002/path.4280. Review. PubMed PMID: 24114677; PubMed Central PMCID: PMC4090031.

Barnes SL, Quarles CC, Yankeelov TE. Modeling the effect of intra-voxel diffusion of contrast agent on the quantitative analysis of dynamic contrast enhanced magnetic resonance imaging. PLoS One. 2014 Oct 2;9(9):e108726. doi:10.1371/journal.pone.0108726. eCollection 2014. PubMed PMID: 25275536; PubMed Central PMCID: PMC4183533.